NYSE$BHVN
Biohaven Ltd old · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for Q2 2024 and provided a review of recent accomplishments and anticipated upcoming developments.
Biohaven reported a net loss of $319.8 million, or $3.64 per share, for the second quarter ended June 30, 2024. The company's cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024. Biohaven is advancing its pipeline with multiple clinical trials underway and expects several milestones in 2024 and 2025.
- Reported positive interim data from Phase 1 study of BHV-1300, a Molecular Degrader of Extracellular Proteins (MoDE™), showing dose-dependent and rapid IgG reductions.
- Advancing novel ion channel program with 5 Phase 2/3 trials underway for BHV-7000 in epilepsy and mood disorders, and positive Phase 1 data for TRPM3 antagonist BHV-2100.
- Taldefgrobep alfa progressing on track with Phase 3 topline data in spinal muscular atrophy (SMA) and Phase 2 trial initiation in obesity expected in 2H 2024.
- Advancing registrational programs for Parkinson’s disease and prevention of Amyloid-Related Imaging Abnormalities (ARIA) following interactions with the FDA for Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) selective inhibitor, BHV-8000.
Headline financials
Revenue & EPS history
Biohaven · Revenue · Quarterly
$0
Forward guidance
Biohaven anticipates achieving significant milestones in 2024 and 2025 across numerous programs.
Tailwinds
- Continue 5 ongoing Phase 2/3 trials with BHV-7000 in focal epilepsy, idiopathic generalized epilepsy, MDD, and bipolar disorder
- Topline results from a new RWE protocol of 3-year data from troriluzole treated patients in SCA in 2H 2024
- Conduct interim analysis of the second Phase 3 OCD trial in 2H 2024 and report topline data from first Phase 3 OCD trial in 1H 2025
- Initiate Phase 2 trial with taldefgrobep in obesity in 2H 2024
- Report topline data from Phase 3 trial with taldefgrobep in SMA in 2H 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q2 2024
-0.5%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+7.7%
Avg return
30 days after
50%
7 / 14 earnings
Positive
+12.6%
Q2 2024
Best reaction
-12.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.7% | -16.0% | -17.0% | |
| Q3 2024 | -6.5% | +0.5% | +28.3% | |
| Q3 2025 | -5.7% | +0.5% | +28.3% | |
| Q2 2025 | -9.0% | +6.6% | -5.0% | |
| Q1 2025 | +0.0% | -3.7% | -5.2% | |
| Q4 2024 | -2.2% | -7.1% | -36.3% | |
| Q2 2024 | +12.6% | +13.7% | +6.7% | |
| Q1 2024 | -12.5% | -8.7% | -17.5% | |
| Q4 2023 | +4.7% | +24.0% | +15.6% | |
| Q3 2023 | +1.0% | +4.6% | +30.9% | |
| Q2 2023 | +3.1% | +3.4% | -3.3% | |
| Q1 2023 | +5.3% | +2.2% | +72.6% | |
| Q4 2022 | +10.4% | +5.4% | +10.8% | |
| Q3 2022 | +1.2% | +2.2% | -0.9% | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro